Prime Highlights:
- AstraZeneca announces a $15 billion investment to expand its research, development, and manufacturing operations in China.
- The funding will focus on high-growth areas such as cancer, blood, and autoimmune diseases, while supporting its R&D network in Beijing and Shanghai.
Key Facts:
- The investment will run through to 2030 and strengthen AstraZeneca’s production and research capabilities.
- China’s pharmaceutical sector is growing rapidly, with Chinese companies now responsible for around 20% of drugs in global development.
Background:
AstraZeneca will invest $15 billion to expand its research and manufacturing in China.
The investment, running until 2030, will boost AstraZeneca’s drug research and manufacturing, focusing on cancer, blood, and autoimmune diseases. As part of the expansion, the company plans to enhance its work in cell therapy and radioconjugate technologies, two fields seen as critical to next-generation cancer treatments.
AstraZeneca will also upgrade its existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, while building new facilities across the country. AstraZeneca currently runs four manufacturing plants in China that supply medicines locally and to more than 70 global markets.
In addition to manufacturing, the funding will support the expansion of AstraZeneca’s research network in China, including its strategic R&D centres in Beijing and Shanghai. The move is part of AstraZeneca’s long-term plan to benefit from China’s growing innovation and skilled workforce.
The announcement came during UK Prime Minister Keir Starmer’s visit to Beijing, aimed at boosting UK-China economic ties. Starmer said the expansion would help the British drugmaker grow globally amid rising competition in life sciences.
China’s pharmaceutical industry has grown fast in recent years, supported by new regulations and more investment in drug research. AstraZeneca has joined this growth through major deals with Chinese biotech firms, including a big agreement with CSPC in 2025.
